不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效及安全性分析

Clinical efficacy and safety of different doses of simvastatin in elderly patients with hypertension and hyperlipidemia

目的探讨分析不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效及安全性。方法随机选取2014年1月~2016年12月期间我院收治的老年高血压合并高脂血症患者60例,按照随机平行的原则将这60例患者均分为对照组和观察组,各30例,观察组的30例患者进行40mg辛伐他汀治疗,对照组的30例患者进行20mg辛伐他汀治,观察比较两组患者的治疗效果以及治疗后的不良反应情况。结果观察组患者用药12周后的治疗总有效率为96.67%,明显高于对照组患者用药12周后的治疗总有效率86.67%;两组患者治疗前的血脂水平无显著差异;观察组患者治疗后总胆固醇为(3.89±1.62)mmol/L、甘油三酯(1.12±0.21)mmol/L、低密度蛋白(1.21±0.20)mmol/L以及高密度蛋白(1.91±0.34)mmol/L均优于对照组患者治疗后的总胆固醇(5.23±1.38)mmol/L、甘油三酯(1.45±0.22)mmol/L、低密度蛋白(1.02±0.34)mmol/L以及高密度蛋白(2.34±0.67)mmol/L,差异具有统计学意义(P<0.05);观察组30例患者中有1例患者出现恶心、有1例患者呕吐、有1例患者头痛;观察组30例患者中有1例患者出现恶心、有2例患者呕吐、有1例患者头痛,两组患者的不良反应情况无统计学差异(P>0.05)。结论辛伐他汀治疗老年高血压合并高脂血症的安全性肯定,应用40mg辛伐他汀治疗老年高血压合并高脂血症临床效果更好。

Objective To investigate the clinical efficacy and safety of different doses of simvastatin in the treatment of elderly hypertensive patients with hyperlipidemia. Methods 60 cases of elderly patients with hypertension and hyperlipidemia who were treated in our hospital from January 2014 to December 2016 were randomly selected. According to the principle of random parallel, the 60 patients were divided into the control group and the observation group, each with 30 cases. 30 patients in the observation group were treated with 40rag simvastatin, and 30 patients in the control group were treated with 20mg Simvastatin. The treatment effect and adverse reaction after treatment were observed and compared between the two groups. Results The total effective rate of the observation group after 12 weeks treatment was 96.67%, which was obviously higher than 86.67% of the control group. There was no significant difference in serum lipid before treatment in the two groups; After treatment, total cholesterol （3.89± 1.62）mmol/L, Triglyceride （1.12 ± 0.21）mmol/L, low density lipoprotein （1.21 ± 0.20）mmol/L and high density lipoprotein （1.91± 0.34）mmol/L of the observation group were better than the total cholesterol （5.23 ±1.38）mmol/L, Triglyceride （1.45 ± 0.22）mmol/L, low density lipoprotein （1.02 ± 0.34） mmol/L and high density lipoprotein （2.34 ± 0.67）mmol/L of the control group, the difference was statistically significant （P 〈 0,05）; Of the 30 patients in the observation group, 1 had nausea, 1 had vomiting, and 1 had headache, Of the 30 patients in the observation group, 1 had nausea, 2 had vomiting, and 1 had headache, There was no significant difference in the adverse reactions between the two groups （P 〉 0.05）. Conclusion The safety of simvastatin in the treatment of senile hypertension associated with hyperlipidemia has been confirmed. The clinical efficacy of 40mg simvastatin in elderly hypertensive patients with hyperlipidemia is better.